BioCentury
ARTICLE | Company News

Aveva Drug Delivery Systems, BioDelivery, MonoSol Rx, Meda neurology , drug delivery news

March 5, 2012 8:00 AM UTC

MonoSol said that it will submit a response to a non-final action issued by the U.S. Patent & Trademark Office (PTO) last month rejecting all claims of its U.S. Patent No. 7,425,292 covering methods of making drug-containing films. The action accompanied the PTO's order granting an instant ex parte reexamination of the patent as requested by BioDelivery in January. The deadline for MonoSol's response is two months from Feb. 16. According to MonoSol, the claims of the '292 patent "remain valid and in full force" until the PTO issues a final ruling. The company said that it is confident that the PTO will "confirm the patentability" of the '292 patent claims (see BioCentury, Feb. 27).

The '292 patent is one of three included in the company's ongoing patent infringement suit against Aveva, BioDelivery and Meda in the U.S. District Court for the District of New Jersey. MonoSol is alleging that the defendants' manufacture and marketing of Onsolis BEMA fentanyl infringes the '292 patent and U.S. Patent Nos. 7,357,891 and 7,824,588, which cover methods of preparing drug-containing films. ...